ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1098

Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis

Iago Pinal-Fernandez1, Katherine Pak2, Albert Gil-Vila3, Andres Baucells4, Benjamin Plotz5, Maria Casal-Dominguez6, Assia Derfoul7, Maria Angeles Martinez4, Albert Selva-O'Callaghan3, Sara Sabbagh8, Frederick W. Miller1, Lisa G. Rider9, Lisa Christopher-Stine10 and Andrew Mammen6, 1National Institutes of Health, Bethesda, MD, 2NIAMS, NIH, Bethesda, MD, 3Vall d’Hebron Hospital, Barcelona, Spain, 4Sant Pau Hospital, Barcelona, Spain, 5Division of Rheumatology, New York University Langone Health, New York, NY, 6NIH, Bethesda, MD, 7NIAMS, NIH, Bethesda, 8Division of Rheumatology, Department of Pediatrics, Medical College of Wisconsin, Washington, DC, 9Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, 10Johns Hopkins University, Baltimore, MD

Meeting: ACR Convergence 2020

Keywords: , , , ,

Session Information

Date: Sunday, November 8, 2020

Session Title: Muscle Biology, Myositis & Myopathies Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.

Methods: In this longitudinal cohort study, anti-cortactin autoantibody tiers were assessed by ELISA in 670 adults and 343 juvenile myositis patients as well as 202 adult and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. The clinical features of patients with and without anti-cortactin autoantibodies were also compared.

Results: The prevalence of anti-cortactin autoantibodies was not different between all adult myositis patients compared to adult healthy controls (11% vs. 8%; p=0.2). However, compared to adult healthy controls, anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%, p=0.005), particularly those with co-existing anti-Mi2 (24%, p=0.03) or anti-NXP2 (23%, p=0.04) autoantibodies. In adult myositis, anti-cortactin was associated with DM-skin involvement (62% vs. 38%, p=0.03), dysphagia (36% vs. 17%, p=0.02) and co-existing anti-Ro52 (47% vs. 26%, p=0.001) or anti-NT5C1a autoantibodies (59% vs. 33%, p=0.001). Moreover, the titers of anti-cortactin antibodies were higher in patients with interstitial lung disease (0.15 vs. 0.12 arbitrary units, p=0.03). The prevalence of anti-cortactin autoantibodies was no different in juvenile myositis (2%) or any juvenile myositis subgroup compared to juvenile healthy controls (4%). Nonetheless, juvenile myositis patients with these autoantibodies had a higher prevalence of mechanic’s hands (25% vs. 7%; p=0.03), a higher number of hospitalizations (2.9 vs. 1.3, p=0.04) and lower peak CK values (368 vs. 818 IU/L, p=0.02).

Conclusion: The prevalence of anti-cortactin autoantibodies is only increased in adult DM patients with co-existing anti-Mi2 or anti-NXP2 autoantibodies. In adults, anti-cortactin autoantibodies are associated with dysphagia and interstitial lung disease.

Disclosure: I. Pinal-Fernandez, None; K. Pak, None; A. Gil-Vila, None; A. Baucells, None; B. Plotz, None; M. Casal-Dominguez, None; A. Derfoul, None; M. Martinez, None; A. Selva-O'Callaghan, None; S. Sabbagh, None; F. Miller, None; L. Rider, NIEHS, NIH, 2, Cure JM Foundation, 2, Bristol Myers Squibb, 2, Hope Pharmaceuticals, 2, Eli Lilly and Company, 9, MedImmune/AstraZeneca, 9; L. Christopher-Stine, None; A. Mammen, None.

To cite this abstract in AMA style:

Pinal-Fernandez I, Pak K, Gil-Vila A, Baucells A, Plotz B, Casal-Dominguez M, Derfoul A, Martinez M, Selva-O'Callaghan A, Sabbagh S, Miller F, Rider L, Christopher-Stine L, Mammen A. Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anti-cortactin-autoantibodies-are-associated-with-key-clinical-features-in-adult-myositis-but-are-rarely-present-in-juvenile-myositis/. Accessed January 18, 2021.

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-cortactin-autoantibodies-are-associated-with-key-clinical-features-in-adult-myositis-but-are-rarely-present-in-juvenile-myositis/